Researchers assessed whether depression in the presence or absence of previous GI symptoms is associated with a future diagnosis of IBD.
Investigators evaluated the association between regular proton pump inhibitor use and the risk for inflammatory bowel disease and its subtypes.
Investigators aimed to show the efficacy of transcriptome-wide association studies in predicting transcriptional risk scores for disease complications requiring colectomy in patients with ulcerative colitis.
Researchers sought to determine whether alternative stable states exist in the intestinal ecosystem and if they could affect remission from ulcerative colitis.
Investigators analyzed the association between consumption of ultra-processed foods and risk for Crohn disease and ulcerative colitis.
Researchers investigated the preclinical characteristics, safety, pharmacokinetics, pharmacodynamics, and efficacy of PTG-100 in patients with moderate to severe UC.
Authors assessed the safety and efficacy of current methods for managing abdominal pain in patients with ulcerative colitis.
An ulcerative colitis exclusion diet (UCED) shows promise as an independent therapy for patients with refractory disease.
The researchers found that atorvastatin treatment had the highest inverse correlation with the ulcerative colitis gene signature among non-oncolytic FDA-approved therapies.
The applications are supported by data from two 2two phase 3 induction studies and one 1 maintenance study.
Researchers described the evolution of dietary patterns and the outcomes they have on the gut microbiome, immune function, and inflammation in people with IBD.
One key factor that has developed increasing research interest is the role of a patient’s BMI, specifically those with obesity (BMI > 30 kg/m2), in the development of IBD.
Researchers aimed to determine whether gut microbiota are associated with relapse and treatment response in patients with ulcerative colitis.
Investigators examined the effect of mesalazine plus somatostatin and bifid triple viable capsules on plasma inflammatory factors and T cell frequency in patients with ulcerative colitis.
Investigators assessed the efficacy of a machine learning tool that predicts steroid-free clinical remission in patients with ulcerative colitis receiving vedolizumab therapy.
Investigators outlined risk factors for ulcerative colitis relapse in patients undergoing dose reduction of oral 5-aminosalicylic acid.
Investigators reviewed the current clinical presentations and treatment options for extraintestinal manifestations in patients with inflammatory bowel disease.
Researchers assessed the practices favored by pediatric gastroenterologists for combination immunosuppression in patients with pediatric inflammatory bowel disease.
New index shows strong correlation with endoscopically determined disease activity
Investigators reviewed the recent research on the biological function of calprotectin in inflammatory diseases.